Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mushtaq Shah

Gastroenterology Greenbelt, MD Medical Doctor

NPI 1043396633 CMS profile 138654

7227 Hanover Pkwy Ste A, Greenbelt, MD 20770

Open in the dashboard

General payments

$4,054

304 records reported · program years 2019–2025

Research payments

$857

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$150,490 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Mushtaq Shah of Greenbelt, MD is reported in the CMS Open Payments database as having received $4,054 across 304 general payments and $857 in research payments paid to them. Separately, studies naming them as principal investigator received $150,490 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 66th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $518 26
2024 General $463 24
2023 General $554 40
2022 General $547 46
2021 General $759 62
2021 Research $857 1
2020 General $739 59
2019 General $474 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mushtaq Shah
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Mushtaq Shah were reported at $518. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Mushtaq Shah Gastroenterology median Middle half National median
2019 $474 $417 $126–$1,100 $163
2020 $739 $224 $74–$624 $114
2021 $759 $352 $106–$1,054 $132
2022 $547 $448 $129–$1,270 $149
2023 $554 $533 $150–$1,390 $160
2024 $463 $605 $160–$1,606 $164
2025 $518 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,443 154 payments
  2. Gilead Sciences, Inc. $438 28 payments
  3. Cumberland Pharmaceuticals, Inc. $359 16 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $265 16 payments
  5. Janssen Biotech, Inc. $257 17 payments
  6. AbbVie, Inc. $192 11 payments
  7. Ironwood Pharmaceuticals, Inc $176 10 payments
  8. Celgene Corporation $150 9 payments
  9. Madrigal Pharmaceuticals $124 6 payments
  10. RedHill Biopharma Inc. $106 6 payments
  11. Other $545 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,797 277 payments
  2. Education $244 26 payments
  3. Entertainment $13 1 payment
Products named General payments · program years 2019–2025
  1. XIFAXAN $1,319 117 payments
  2. TRULANCE Gastroenterology $522 55 payments
  3. TRULANCE Gastroenterology $414 45 payments
  4. KRISTALOSE $296 12 payments
  5. STELARA $212 15 payments
  6. LINZESS Gastroenterology $192 11 payments
  7. Linzess Gi $176 10 payments
  8. ZEPOSIA $150 9 payments
  9. ENTYVIO $145 6 payments
  10. Talicia $106 6 payments
  11. Other $1,458 87 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $857 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

633

Median for Gastroenterology: 569

Drug cost

$93,843

Median for Gastroenterology: $104,976

Branded share of claims

37.3%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 63 $59,504
Mesalamine Generic 40 $19,085
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 134 $7,379
Omeprazole Generic 189 $3,501
Tenofovir Disoproxil Fumarate Generic 12 $869
Pantoprazole Sodium Generic 42 $824
Famotidine Generic 51 $770
Dicyclomine Hcl Generic 28 $712
Esomeprazole Magnesium Generic 23 $533
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 23 $323

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$63,725

Medicare's payments for the services billed

Medicare patients

245

Average age 72

Services billed

451

151 women, 94 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 52%
Arthritis 49%
Chronic kidney disease 27%
Ischemic heart disease 22%
Cancer 19%
Heart failure 16%
Atrial fibrillation 11%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KRISTALOSE
  • Cumberland Pharmaceuticals, Inc. $97
$97 — —
LINZESS
  • Ironwood Pharmaceuticals, Inc $43
  • AbbVie, Inc. $12
$54 63 —
STELARA
  • Janssen Biotech, Inc. $42
$42 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $32
$32 — —
RESMETIROM
  • Madrigal Pharmaceuticals $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

305 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record